Printer Friendly

IMCERA'S MALLINCKRODT MEDICAL UNIT AND SANDOZ PHARMA LTD. SIGN AGREEMENT TO SHARE MOLECULAR RESEARCH

 NORTHBROOK, Ill., Dec. 16 /PRNewswire/ -- IMCERA Group Inc. (NYSE: IMA) announced today that its Mallinckrodt Medical unit of St. Louis and Sandoz Pharma Ltd. of Basel, Switzerland, have signed an agreement to share technology on molecules that can be developed into future radiodiagnostic and radiotherapeutic products.
 Sandoz has the technology to generate unlabeled molecules for intended medical purposes, while Mallinckrodt Medical has the technology to radiolabel them. Under the agreement, the companies will work together to develop and radiolabel molecules. Sandoz will grant Mallinckrodt Medical exclusive worldwide rights to register, manufacture, market and sell diagnostic products that result from the joint research; Mallinckrodt Medical will grant Sandoz exclusive rights to therapeutic products that emanate from the joint effort.
 Both companies have agreed to cooperate in clinical studies of products that result from the cooperative venture. The five-year agreement contains clauses that allow for contract extensions.
 "This agreement will enable both companies to draw upon their technological strengths to develop products that may ultimately provide new diagnostic and therapeutic approaches to benefit the health care profession worldwide," said Robert G. Moussa, president and chief executive officer of Mallinckrodt Medical.
 The new agreement grows out of an earlier contract under which Mallinckrodt Medical applied research done by Sandoz and the University Hospital Dijkzigt, Rotterdam, on an analogue of somatostatin, called octreotide, to develop and seek worldwide regulatory approvals for the radiolabeled diagnostic drug, OctreoScan(R) 111. The new diagnostic agent is designed to help physicians in early detection for locating tumors and their metastases in many parts of the body.
 Sandoz developed the drug Sandostatin(R), used to treat certain tumors, from its octreotide research.
 Sandoz Pharma Ltd. is among the leading pharmaceutical companies of the world. Its products are used in the areas of organ rejection after transplantation, of endocrinological, immunological, cardiovascular and central-nervous-system disturbances, as well as of asthma, allergies and pain.
 Mallinckrodt Medical is a leading producer of radiopharmaceuticals in the $800 million worldwide nuclear medicine market, which is expected to grow to about $1.1 billion by 1995.
 With fiscal 1992 net worldwide sales of $620 million and operating earnings of $128 million, Mallinckrodt Medical is a major supplier of products for radiology, cardiology, nuclear medicine, anesthesiology and critical care. Its products are sold in more than 100 countries and are used by more than 7,000 health care facilities in the United Sates.
 IMCERA, a Fortune 250 company with fiscal 1992 net sales of more than $1.7 billion, has two other international, technology-based businesses--Mallinckrodt Specialty Chemicals of Chesterfield, Mo., and Pitman-Moore of Lake Forest, Ill.
 -0- 12/16/92
 /CONTACT: Dave Prichard, corporate staff vp of IMCERA Group Inc., 708-205-2270/
 (IMA)


CO: IMCERA Group Inc.; Sandoz Pharma Ltd. ST: Illinois IN: MTC SU: JVN

WB -- NY044 -- 7676 12/16/92 11:38 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 16, 1992
Words:467
Previous Article:WARNER INSURANCE SERVICES, INC. ANNOUNCES RECORD RESULTS FOR THE FISCAL YEAR ENDED OCT. 31, 1992
Next Article:AT&T DECLARES QUARTERLY DIVIDEND
Topics:


Related Articles
AFFYMAX N.V. ANNOUNCES RESEARCH COLLABORATION WITH SANDOZ PHARMA LTD.
AFFYMAX N.V. ANNOUNCES RESEARCH COLLABORATION WITH SANDOZ PHARMA LTD.
SANDOZ ANNOUNCES $75M ALLIANCE WITH THE NEUROSCIENCES INSTITUTE, EXPANDS COMMITMENT TO CNS DISCOVERY
SYSTEMIX AND SANDOZ PHARMA TO SCREEN AND TEST THERAPEUTIC AGENTS FOR HIV INFECTION
MALLINCKRODT MEDICAL, INC. ESTABLISHES NATIONAL DISTRIBUTION OF ITS PROPRIETARY PRODUCTS WITH MEDI+PHYSICS, INC.
PHARMACOPEIA AND SANDOZ PHARMA ANNOUNCE A RESEARCH AND DEVELOPMENT COLLABORATION
TRIPOS SOFTWARE ADOPTED BY SANDOZ PHARMA LTD. AT KEY RESEARCH SITES WORLDWIDE
ORION PHARMA GRANTS BROAD MARKETING RIGHTS OF PARKINSON'S DISEASE DRUG TO SANDOZ PHARMA LTD.
Molecular Biosystems, Mallinckrodt Expand Partnership for Marketing of FS069
Mallinckrodt Signs 5-Year Agreement with Indian Company, Cadila Pharmaceuticals Ltd.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters